Mary Ellen Banker

Publications by Year

Research Areas

Cytokine Signaling Pathways and Interactions, Hormonal Regulation and Hypertension, Psoriasis: Treatment and Pathogenesis, Estrogen and related hormone effects, Crystallization and Solubility Studies

Most-Cited Works

• → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)189 cited
• → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
• → Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases(2018)163 cited
• → Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans(2017)160 cited
• → Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors(2018)74 cited
• → The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization(2020)64 cited
• → ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling(2014)60 cited
• → Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists(2016)60 cited
• → The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism(2011)55 cited
• → Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide(2016)55 cited